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Abstract
Parental concerns about the safety of childhood vaccinations began in the 1990’s and continue until today. A primary
concern of many parents is whether the adjuvants and preservatives added to the vaccines have the potential to cause
neurodevelopmental disorders in young children. An overview of various studies was done to determine if thimerosal
affects childhood neurodevelopment with studies suggesting that thimerosal potentially causes neurodevelopmental
disorders. However, some studies suggest the opposite. As a result it is impossible to conclude whether thimerosal
affects childhood neurodevelopment. However, measures should be taken to remove thimerosal from the childhood
vaccination schedule. Additionally, the studies must be done to determine if other components of vaccines can have
adverse effects on the developing nervous system.
Introduction
Thimerosal, a mercury-based vaccine preservative, has been a
source of controversy since the 1990’s. Many parents worried
that the presence of mercury in vaccinations could lead to autism spectrum disorder and other medical problems.The Center
for Disease Control and the American Academy of Pediatrics
collectively decided, in July 1999, to remove thimerosal containing vaccines (Baker, 2007). According to the Food and Drug
Administration thimerosal has undergone various studies and it
“has a long record of safe and effective use preventing bacterial
and fungal contamination of vaccines, with no ill effects established other than minor local reactions at the site of injection”
(FDA, 2015). In the United States, the only vaccines that currently
contain thimerosal are MPSV4-Menomune (vaccine for meningitis), Td (booster for tetanus and dipthereia) manufactured by
Decavac,Td (Mass Biologics), Dt (Sanofi) and three of the influenza vaccines (Hamborsky et al., 2015). Some researchers posit that
there may be a link between thimerosal and neurodevelopmental
problems. Other studies demonstrate that thimerosal does not
have such effects.This study was done to determine if thimerosal
poses a risk on childhood neurodevelopment.

Purpose of Preservatives and Adjuvants in Vaccines:
The United States Code of Federal Regulations (CFR) mandates
the addition of preservatives to vaccines in vials containing
multiple doses to prevent contamination of the vaccine after
multiple needle insertions. Previously, some vaccines became
contaminated during the manufacturing process. As a result, the
CFR required the addition of preservatives to kill the microbes
that contaminated the vaccine.With the advancement of aseptic
manufacturing of vaccines, the necessity of putting preservatives
in vaccines has decreased. As a result, many vaccines do not
currently require the addition of preservatives into them (Geier
et al., 2010). Adjuvants are added to vaccines to help the body
develop immunity after injection of killed vaccines. Adjuvants
are added to minimize the amount of antigens the body needs
to be exposed to in order to generate an immune response
(Petrovsky, Aguilar, 2004).

Methyl Mercury vs. Ethyl Mercury
The main question behind the debate over thimerosal is the

comparison between ethyl and methyl mercury. Mercury exposure has been found to cause severe health problems such as
damage to the nervous, digestive and immune systems. Methyl
mercury specifically has been found to affect the developing
brain and nervous system. The most susceptible individuals
to methyl mercury are fetuses exposed to methyl mercury in
utero (WHO, 2013). Methyl mercury has been proven to cause
neurotoxicity since the 1960’s. Mothers who ate fish in water
contaminated by methyl mercury during their pregnancy, gave
birth to children with mental retardation, blindness, and spasticity. However, mothers exposed to methyl mercury were less
adversely affected than the infants. A study on New Zealand
neonates born from mothers who had hair concentrations of
mercury greater than six micrograms per gram found that infants with greater mercury exposure had a lower Intelligence
Quotient (IQ) by three points. The United States National
Academy of Sciences decided that fetal exposure to methyl
mercury can be toxic even at low concentrations (Grandjean,
Landrigan, 2006).
The Food and Drug Administration states that the legal guidelines for mercury exposure were decided based on studies
on methyl mercury. However, thimerosal’s derivative is ethyl
mercury which as a result of being slightly chemically different can have different effects on the body than methyl mercury. Additionally, high levels of ethyl mercury were found to
have severe neurological effects on both adults and children.
However, the effects of low dose ethyl mercury exposure have
not been determined (Offit, Jew, 2003). As there is no definitive
study with a safe exposure concentration of ethyl mercury and
the differences in the effects of methyl and ethyl mercury are
not known, the FDA considers ethyl mercury to be as toxic
as methyl mercury (FDA, 2015). Ethyl mercury was found to
increase the tissue concentration of inorganic mercury more
than methyl mercury does in rhesus macaques (Hornig et al.,
2004). Ethyl mercury levels in the brain post exposure are lower
than those of methyl mercury (Clements, 2004). A main source
of the controversy on thimerosal is the question if methyl and
ethyl mercury have the same or different effects on the body.
Some studies show that thimerosal’s ethyl mercury does indeed
have neurotoxic effects, while others argue that it does not.
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Methods
A variety of research papers on the subject were collected from
Google Scholar, EBSCO and ProQuest. Access to EBSCO and
ProQuest was given through the Touro College Library System.
Key words used, were thimerosal, neurodevelopment, adjuvants,
vaccines, adverse effects and immunizations.

Results
Thimerosal and Neurodevelopment:
Thimerosal Causes Neurodevelopmental Disorders
In the 1990’s many infants had mercury exposure higher than
that recommended by the EPA, FDA, and the United States
Agency for Toxic Substances and Disease Registry (ATSDR) for
methyl mercury.This was a result of both Thimerosal Containing
Vaccine (TCV) and environmental exposure. Methyl mercury is
a compound that is closely related to ethyl mercury, one of
the derivatives of thimerosal. A study of 278,624 infants born
between 1990 and 1996 and recorded in the Vaccine Safety
Datalink was done in order to determine if thimerosal indeed
has neurotoxic effects on infants and young children. During
those years the main vaccines containing thimerosal were the
Haemophilus Influenza Type b (Hib), hepatitis B, acellular DTaP
(Diptheria, Tetanus, acellular Pertussis), and whole-cell DTP. The
amount of mercury exposure was calculated for each individual
based on the amount and concentration of mercury in each
of the mercury containing vaccines. The mercury exposure was
measured between two intervals, birth and 7 months and birth
and 13 months. The rate of increase in six neurodevelopmental
disorders were calculated for each additional 100 microgram of
mercury the children were exposed to. Three control disorders
were also observed for each 100 microgram increase in mercury exposure due to thimerosal containing vaccines. (Young et
al., 2008)
The six neurodevelopmental disorders observed were Autism,
Autism Spectrum Disorders (ASD), Hyperkinetic syndrome of
childhood (ADD/ADHD), Developmental/Learning Disorders,
Disturbances of emotions specific to childhood and adolescence, and tics. The control disorders observed were pneumonia, congenital anomalies, and failure to thrive. The study determined that the ratios of each of these disorders increased
with the increased exposure to Thimerosal containing vaccines.
The rate ratios were measured with a confidence interval of
95%. For each 100 microgram increase in mercury exposure
the ratio of hyperkinetic syndrome of childhood increased by
a ratio of 3.15 and Autism and Autism Spectrum disorders increased by ratios of 2.87 and 2.44 respectively. Developmental
and Learning disorders had the lowest ratio of increase, while
hyperkinetic syndrome had the highest. The control disorders
did not have a relatively high increase as a result of higher mercury exposure (Young et al., 2008).
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The levels of autism corresponding to each year in the study
directly correlated to the amount of mercury exposure via vaccine. In 1990 and 1991, hepatitis B and Hib had been added
to the vaccine schedule. After 1992, the DTP vaccine was
combined with Hib vaccine, thus leading to a lower mercury
exposure than there had been when the two vaccines were
kept separate. The levels of autism in those years fluctuate directly with the fluctuations of mercury administered via vaccine
(Young et al., 2008).
Another study compared the toxicities of the four most common preservatives added to vaccines in the United States.These
four compounds were 2-phenoxyphenol, phenol, Thimerosal,
and benzethonium chloride. These compounds were administered to human neurons in vitro and to bacterial cells. The
toxicities to each type of cell were measured. The cytotoxicity towards human neuroblastoma cells was measured after
24 hours of incubation. Thimerosal was found to be the most
toxic of the four preservatives added to vaccines. Each of the
four compounds was also tested on bacterial cells. A thimerosal
concentration of ten times the amount added to vaccines was
not able to sufficiently kill bacterial cells within twenty minutes
(Geier et al., 2010).
While there is room to question the certainty of the thimerosal’s effects on children, it his highly likely that thimerosal does
adversely affect the neurodevelopment of susceptible infants. In
some of the studies thimerosal was the only measured variable, while in others thimerosal was taken into account with
other possible neurotoxic environmental exposures. Using the
Gesell Development Score, investigators found no correlation
between thimerosal exposure from vaccines and neurodevelopmental disorders, if the child nursed for the first six months
of life. The GDS was also measured from birth to five years
and once again there was no correlation between thimerosal
exposure and neurodevelopmental disorders. The studies that
took environmental exposure to neurotoxic elements into consideration as well as thimerosal, found that ethyl mercury, one
of the byproducts of thimerosal, has adverse effects on neurodevelopment. The controlled variables were the environmental
factors that were known to affect neuroplasticity. For example,
secondhand smoke, cord blood Hg, and lead (Dorea, 2015).
The Vaccine Adverse Events Reposting System (VAERS) database was used to determine if indeed the rise in childhood
neurodevelopmental disorders was caused by thimerosal exposure due to vaccinations. A comparison was made of the
prevalence of neurodevelopmental disorders after exposure
to either thimerosal containing or thimerosal free DTaP vaccines. Three neurodevelopmental disorders were observed in
this study; autism, personality disorders and mental retardation.

Effects of Vaccine Preservatives and Adjuvants

The participating patients were split into two groups, the first
group had an average mercury exposure of 37.5 microgram,
while the second group had a mercury exposure of 87.5 micrograms. Some of the control adverse events were fever, pain, and
vomiting. The United States Department of Education report
from 2001 was also evaluated to find out how many children
in different age groups suffered from a variety of conditions;
autism, speech disorders, orthopedic or visual impairments, and
deaf-blindness. The amount of mercury the children were exposed to was also compared to the maximum possible amount
of mercury exposure allowed by the FDA (Geier, Geier, 2003).

concentration of thimerosal tested was lower than that found
in TCV, while in some the concentration ranged from nano
to micromolar concentrations. An In vivo study administered
different concentrations of thimerosal to suckling Wistar and
Lewis rats at 7, 9, 11 and 15 days. The thimerosal was found to
decrease pain sensitivity and to significantly accumulate in rat
brains. The concentration of thimerosal found in vaccines had
neurotoxic effects on human neurons in vitro and in laboratory
animals (Dorea, 2011).

Comparing the prevalence of autism, personality disorders and
mental retardation following exposure to thimerosal from the
DTaP vaccine and the thimerosal-free DTaP demonstrated a
linear correlation between mercury exposure and neurodevelopmental disorders. The odds ratio of autism increased by
.029, personality disorders by .012, and mental retardation by
.048 for each microgram of mercury. The odds ratio for each
of these disorders was higher for each of them after exposure
to the DTaP containing thimerosal than for that without it.
The United States Department of Education report also had
increasing ratios in autism and speech disorders. The amount
of febrile seizure, fever, pain, edema, and vomiting was higher
for the thimerosal containing DTaP vaccine group, however the
amount it rose and the increasing amount of mercury exposure
do not directly relate to one another. The study also demonstrated that the amount of mercury the children were exposed
to due to the childhood vaccine schedule in different years had
3.2-32 fold higher amount than that recommended by the FDA
for oral methylmercury. Exposure to mercury intravenously has
more adverse effects on the body than if it has been orally ingested (Geier, Geier, 2003).

A study was done in Poland to determine if there is a correlation between exposure to Thimerosal containing vaccines and
cognitive development in the children’s’ first nine years. All of
these children had been given the DTP and hepatitis B vaccine,
some of which contained thimerosal and some which didn’t.
At different points during the first nine years of life, tests were
done to assess the level of each child’s cognitive development.
All the vaccines that the children were exposed to contained
aluminum as an adjuvant. In the first month of life 69.2% of
the children were exposed to thimerosal, and between the first
month and the 6th month 86.2% of the children were exposed
to thimerosal containing vaccines. The results of each psychological test done were similar for both children who were and
were not exposed to thimerosal. In fact the IQ levels of those
exposed to thimerosal was higher overall than that of the control group. The results of the study displayed no correlation between thimerosal exposure and lower cognitive developmental
levels. (Mrozek-Budzyn et al., 2014).

A study surveying British children found there to be a relationship between hyperactivity and behavioral problems, motor
development and the necessity for speech therapy. Other studies have found that there were significant differences in the
impact of thimerosal on different genders. Male children were
found to have a higher IQ upon exposure, but the exposure
also hampered their behavioral regulation and motor tics. In a
study in Italian children thimerosal was found to detrimentally
affect girls in the areas of language and motor function (Curtis
et al., 2015)
An overview was done by analyzing the results of in vivo and in
vitro studies of the thimerosal’s effects. In the in vitro studies
thimerosal was found to cause mitochondrial damage, reduce
oxidation-reduction activity, cause cell degeneration and cell
death, and increase the levels of fragmented DNA in human
neuroblastoma cells. In some of the overviewed studies the

Thimerosal Does Not Cause
Neurodevelopmental Disorders

Various studies had been done testing thimerosal containing
vaccines on rodents, with results demonstrating that thimerosal
had no neurodevelopmental effects. However, on the rare occasion that there was a problem with the vaccine, a very high dosage of thimerosal had been administered, 250 fold higher than
contained in vaccines. A study was done to compare the effects
of different vaccine schedules on a non-human primate model.
These were chosen as their anatomy and length of development
stages are very similar to those of humans. Neurobehavioral
tests were done on the primates to see the effect of a variety of
vaccine schedules on the primates’ neurodevelopment (Curtis
et al., 2015).
In the study seventy-nine rhesus macaques were split into six
groups. The first group, the control, received saline injections.
The second group received only the MMR vaccine, the third
TCV’s excluding the MMR vaccine. The fourth group was administered the vaccine schedule from the 1990’s, while the fifth
group received the same vaccines with accelerated timing at
a ratio of 4:1. The sixth group was administered the vaccine
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schedule from 2008. In the 1999 vaccine schedule, the TCV’s
were Hepatitis B, DTaP, and Hib. In the 2008 vaccine schedule,
the multiple-dose influenza and meningitis vaccines contained
thimerosal. The pregnant macaques in the 2008 group were
given the influenza vaccines a month before the expected delivery date. (Curtis et al., 2015).
Each of the infant macaques was tested on the Neonatal
Behavioral Assessment Scale to check for nineteen neonatal
reflexes. There was no significant difference in the results of
each of the six groups for the NBAS test, except in one of the
criteria. The macaques were also tested for their object concept performance, their social behavior and the discrimination/
reversal learning and learning set. In each of these tests there
were no significant differences in the results among the groups.
The animals given TCVs reached their goal in fewer trials than
animals in the control group in the reversal learning part of
the test.Thereby demonstrating that thimerosal did not hamper
this area of neurodevelopment.At the age of 12 months the fifth
group had a significantly lower amount of exploring behaviors
than did the control macaques. The fifth group also had a lower
amount of positive behaviors at 2 months, while at 12 months
they had a higher amount of positive behaviors than did the rest
at two months of age the fourth and sixth groups had significantly fewer negative behaviors, however at 12 months there
were no major differences between the six groups (Curtis et
al., 2015).
A study in Denmark, used data from the Danish Psychiatric
Central Research Register to determine if thimerosal exposure leads to autism spectrum disorder. This study was done to
determine if removing thimerosal from vaccines decreased the
incidence of autism. The rates of autism diagnosed from 1971
to 2000 for children in three age groups, ages 2-4, 5-6, and 7-9,
were reviewed. From the years 1961 to 1970 the children were
administered 400 micrograms of thimerosal. From 1971-1992
children were exposed to 250 micrograms of thimerosal. After
1992, vaccines without thimerosal were administered to Danish
children. During this period, 956 children had been diagnosed
with autism. From 1971 to about 1990 the rates of autism remained stable. After 1991, the rates of autism began to increase,
peaking in the year 1999 with the highest incidences occurring
in the first two age groups, between 2 – 6 years of age. Each
of these children had been born after thimerosal containing
vaccines had been removed from the Danish vaccine schedule.
Thereby indicating, that the increase of autism does not relate
to thimerosal exposure (Madsen et. al, 2003).

Aluminum and Neurodevelopment
Studies have demonstrated that in vitro aluminum exposure has
the potential to cause cell death in human neurons. However,
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aluminum has been found to be less cytotoxic than thimerosal (Dorea, Marques, 2009). A study was done to determine if
aluminum exposure as a result of its use as a vaccine adjuvant
is a cause of the rise of autism. Data was taken from the US
Department of Educational Annual Reports to Congress to determine the rates of autism from 1991-2008 for individuals age
6 – 21.The rates of autism were also compared to the aluminum
exposure in regards to the vaccine schedule in other countries.
The data was compared to the concentration of aluminum exposure from pediatric vaccines, below 6 years of age. Results
demonstrated that the highest level of aluminum in comparison was at age 2 months in the United States. Interestingly, the
countries with higher aluminum adjuvant exposure had higher
rate of autism (Tomljenovic, Shaw, 2011).

Discussion
Based on the reported studies there is room to question the
effects of the Thimerosal and vaccines containing it on human
children. Studies done in vitro demonstrate that thimerosal
does cause apoptosis and neurotoxic effects to human neurons (Dorea, 2011). However, results occurring in vitro are not
always a directly comparable to those in vivo, as in vivo it is
difficult to accurately evaluate the concentration of mercury
reaching the individual’s neurons. Additionally, studies done
on Rhesus macaques seem to point out that thimerosal does
not hinder neurodevelopment, in some cases the exposed animals had scored higher than the control (Curtis et al., 2015).
However, the primate model is not necessarily an exact indication as to what would happen to humans when they would be
exposed to the same concentrations of thimerosal, though the
results would be similar as the two bodies function similarly.
Only seventy-nine macaques were surveyed and then split into
six groups, thereby only a small number of macaques represented each vaccine schedule. Therefore, even though the macaque
functions similarly to humans, the validity of the results in comparison to human would need a higher number of macaques in
each group to demonstrate the efficacy of the results.
The study using the Vaccine Safety Datalink uses a large sample
of children, and demonstrates a direct correlation between thimerosal exposure and neurodevelopmental disorders. However,
the study does not take into account environmental exposure
to mercury and other neurotoxins, thereby making it harder to
say with certainty that thimerosal does indeed cause different
neurodevelopmental disorders (Young et al., 2008). The study
also does not take into account the genetics of the children and
the possible predisposition to neurodevelopmental disorders.
However, there does seem to be a strong indication that thimerosal has neurodevelopmental effects, as the prevalence of
autism in various years was directly related to the fluctuations
of mercury in the childhood vaccine schedule, thus indicating
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that children born in years that a vaccine schedule with a higher
concentration of mercury had increased rates of autism.
Additionally, the primate model is not a direct representation
of what would happen in the human models because studies
show that the rate of elimination in the blood and brain differ
for methyl and ethyl mercury in primates and human infants
(Hornig et al., 2004). As a result, ethyl mercury in humans may
cause different mercury levels than it would for the rhesus macaques used in two of the above studies.
Based on the above studies it is hard to conclude whether or
not thimerosal containing vaccines cause neurodevelopmental
disorders. However, some studies do seem to indicate that thimerosal causes autism among other neurodevelopmental disorders. Additionally, thimerosal containing vaccines were found to
cause a significant amount of damage to human neurons in vitro,
including cell death. As a result, further study must be done
to determine with certainty the true effects of thimerosal on
human neurodevelopment.
As one study demonstrated that the concentration of thimerosal found in human vaccines was not sufficient to kill bacterial cells, the question arises as to the necessity of placing
thimerosal into vaccines. Additionally, after administration of
multiple does DTP and Td vaccines that contained thimerosal
as a preservative there were outbreaks of pyogenic infections.
Indicating that despite the addition of preservatives to vaccines,
microbial contamination can still occur (Ball et all, 2001). One of
the main vaccines today currently containing thimerosal is the
multiple-dose influenza vaccine.Thimerosal is added as a preservative to prevent bacterial contamination of the vaccine. If the
concentration of thimerosal needed to effectively rid the vaccine of bacteria is higher than the concentration of thimerosal
in the vaccine, then it is likely that the thimerosal is not doing its
job. Steps should be taken to remove thimerosal from vaccines
as there is a strong potential that thimerosal does indeed cause
neurodevelopmental problems. If thimerosal is kept in vaccines,
it should be determined whether the benefits thimerosal brings
to the vaccine outweigh the risks brought onto children when
they are vaccinated.
Fetuses, neonates, and other small children are the most susceptible to neurodevelopmental damage, as these are the periods of brain growth (WHO, 2013 and Dorea, 2015). The World
Health Organizations states a fetus is the most susceptible to
neurotoxic factors (WHO, 2016). Additionally, during the prenatal and early postnatal stages the Blood Brain Barrier (BBB)
is not fully developed. As a result, the likelihood of neurotoxins
crossing the BBB is higher in fetuses and newborns (Tomljenovic
and Shaw, 2011). As the risks of thimerosal exist and there is

not conclusive proof that there is not neurotoxicity, injecting
pregnant woman and babies with vaccines containing thimerosal
should be avoided, as these are the ages most critical to childhood neurodevelopment. For example, the Center for Disease
Control currently recommends that the influenza vaccine be
administered to pregnant woman as a woman suffering from influenza during her pregnancy is at great risk (Center for Disease
Control, 2015). Pregnant woman are more likely to have longer
stays at the hospital as a result of respiratory illnesses, than
when not pregnant (American College of Obstetricians and
Gynecologists). There seems to be a clear benefit of a pregnant
woman being immunized to influenza. However, based on the
information above, there is clearly a potential that thimerosal
causes neurodevelopmental disorders, and this stage is where
the fetus is the most susceptible to neurotoxins. As a result,
measures should be taken to ensure that pregnant woman are
given the influenza vaccine that does not contain thimerosal.
Additionally, the postnatal stages till adolescence are still stages
of neurodevelopment. As thimerosal potentially causes neurodevelopmental disorders, the benefits of thimerosal containing
vaccines must be evaluated to see if they actually outweigh the
risks presented by thimerosal exposure.

Conclusions
There is no definitive evidence to conclusively determine if
thimerosal causes neurodevelopmental disorders in young
children. However, the potential for thimerosal to cause neurodevelopmental disorders gives rise to question the potential
harm of the other agents used as preservatives and adjuvants
in vaccine today. One of the main adjuvants used in vaccines
today is Aluminum, which does seems to have the potential to
affect neurodevelopment, specifically causing autism spectrum
disorder. As vaccines are being administered to susceptible individuals, further studies should be done to all the chemicals
added to vaccines to determine if they are really safe, and if the
benefits they bring to the vaccine outweigh the risks.
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